Deforolimus shows promise in patients with advanced malignancies

March 2008
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p47
The article discusses research on the effectiveness of deforolimus in treating patients with advanced solid malignancies. It references a study published in a 2008 issue of the "Journal of Clinical Oncology." The researchers discovered that the drug is well tolerated with some promising antitumor activity among cancer patients. The maximum tolerated dose of deforolimus was found to be 18.75 milligrams per day (mg/day).


Related Articles

  • Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan. Kobayashi, Michiya; Oba, Koji; Sakamoto, Junichi; Kondo, Ken; Nagata, Naoki; Okabayashi, Takehiro; Namikawa, Tsutomu; Hanazaki, Kazuhiro // Gastric Cancer;Mar2007, Vol. 10 Issue 1, p52 

    We aimed to clarify the relationship between the maximum tolerated dose and plasma concentration of paclitaxel in Japanese patients with gastric cancer on a weekly paclitaxel administration regimen. Thirty-three patients with advanced or recurrent gastric cancer were treated with escalating...

  • Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours. Chen, X.; Oza, A. M.; Kusenda, Z.; Yi, Q-L.; Kochman, D.; Moore, M. J.; Davis, A. J.; Siu, L. L. // British Journal of Cancer;8/18/2003, Vol. 89 Issue 4, p617 

    This phase I study was conducted to determine the recommended phase II doses, safety profile, and antitumour activity of a combination regimen of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours. Cisplatin and epirubicin were given at fixed...

  • Amifostine not protective against paclitaxel-associated neuropathy.  // Reactions Weekly;2/14/2004, Issue 988, p4 

    Presents the results of a study that determined the effects of amifostine on the neurotoxicity of high-dose paclitaxel in patients with breast cancer receiving antineoplastic therapy. Dosage of the antineoplastic drugs given to subjects; Peripheral neuropathy scores following the antineoplastic...

  • A phase I and pharmacokinetic study of indisulam in combination with carboplatin. Dittrich, C.; Zandvliet, A. S.; Gneist, M.; Huitema, A. D. R.; King, A. A. J.; Wanders, J. // British Journal of Cancer;2/26/2007, Vol. 96 Issue 4, p559 

    Indisulam (E7070) is an anticancer agent that is currently being evaluated in phase II clinical studies. A significant reduction in glutathione synthetase and glutathione reductase transcripts by indisulam provided a molecular basis for its combination with platinum agents. Indisulam...

  • Non-intercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort study. Mattsson, T. O.; Holm, B.; Michelsen, H.; Knudsen, J. L.; Brixen, K.; Herrstedt, J. // Annals of Oncology;May2015, Vol. 26 Issue 5, p981 

    Background: The incidence of non-intercepted prescription errors and the risk factors involved, including the impact of computerised order entry (CPOE) systems on such errors, are unknown. Our objective was to determine the incidence, type, severity, and related risk factors of non-intercepted...

  • Pemetrexed and Carboplatin (PC) Regimen. Waddell, J. Aubrey; Solimando Jr., Dominic A. // Hospital Pharmacy;Nov2009, Vol. 44 Issue 11, p946 

    The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and...

  • Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer. Chachad, Siddharth; Purandare, Shrinivas; Malhotra, Geena; Naidu, Raghu // Cancer Chemotherapy & Pharmacology;Feb2013, Vol. 71 Issue 2, p287 

    Purpose: The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer. Methods: The study was a multicentric, open label, randomized,...

  • Body Surface Area in Dosing Anticancer Agents: Scratch the Surface! Miller, Antonius A. // JNCI: Journal of the National Cancer Institute;12/18/2002, Vol. 94 Issue 24, p1822 

    Editorial. Focuses on the use of body surface area in dosing anticancer agents. Definition of body surface area; Evaluation of the possible side effects of overdosage; Concerns about the safety of drug dosing.

  • Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. Baker, Sharyn D.; Jaap Verweij; Rowinsky, Eric K.; Donehower, Ross C.; Schellens, Jan H.M.; Grochow, Louise B.; Sparreboom, Alex; Verweij, Jaap // JNCI: Journal of the National Cancer Institute;12/18/2002, Vol. 94 Issue 24, p1883 

    The prescribed dose of anticancer agents is most commonly calculated using body surface area as the only independent variable, and it has been shown that this approach still results in large interpatient variability in drug exposure. Here, we retrospectively assessed the pharmacokinetics of 33...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics